Drugs / KD-247
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00917813 | Sep 2007 → ? | HIV infectious disease | The Chemo-Sero-Therapeutic Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD-247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00917813 ↗ |
| Modality | Monoclonal antibody | “a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1” NCT00917813 ↗ |
| Route | Intravenous | “Per cohort subjects randomized to active treatment will receive iv infusions of KD 247 over 2 hours at each dosing visit.” NCT00917813 ↗ |